Nugma Chadha, MD
Internal Medicine · Orlando, FLNPI 1033420492
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Pfizer at 37.4% of the total. Reporting peaked in 2019 at $112 and has fallen 80.4% since, to $22 in 2023. That places this record below the midpoint for internal medicine clinicians in FL, where the typical reported total is $316.
Across 17 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$100
- Johnson & Johnson$65
- AstraZeneca$33
- Novartis$19
- E.r. Squibb & Sons, L.L.C.$13
- Melinta Therapeutics, LLC$13
- plus $25 from 2 others
What the payments were for
- Food & beverage$268100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 6 | $100 |
| Johnson & Johnson | 4 | $65 |
| AstraZeneca | 2 | $33 |
| Novartis | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Melinta Therapeutics, LLC | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$268 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 12 | $2,216 |
| Hydralazine Hcl | 17 | $202 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $83 |
| Pantoprazole Sodium | 17 | $79 |
| ClopidogrelClopidogrel Bisulfate | 11 | $75 |
| Metoprolol Succinate | 12 | $62 |
| Atorvastatin Calcium | 11 | $35 |
| Furosemide | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Orlando
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.